http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Evoke Pharma (EVOK) Reports New Gimoti Data
-
Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
-
Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
-
Evoke Pharma (EVOK) Announces New GIMOTI Patent Listed in FDA Orange Book
-
New GIMOTI Patent Listed in FDA Orange Book
-
Evoke Pharma (EVOK) Granted US Patent for Formulation Patent Covering GIMOTI
-
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
-
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
-
Evoke Pharma (EVOK) and EVERSANA Report Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources
-
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMC
-
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
-
Evoke Pharma (EVOK), EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
-
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
-
Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
-
Evoke Pharma Reports Second Quarter 2022 Financial Results
-
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
-
Patient Experience Survey Reported Positive Findings for GIMOTI®
-
Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
-
Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022
-
Evoke Pharma (EVOK) and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
-
Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
-
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study
-
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI
-
Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders’ (IFFGD) August Gastroparesis Awareness Month
-
Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGD’s Industry Council
-
Evoke Pharma (EVOK) and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
-
Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
-
Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray
-
Evoke Pharma (EVOK) Announces Positive Findings from GIMOTI Market Research Study
-
Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study
-
Evoke and EVERSANA Announce Commercial Launch of Gimoti™
-
Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™
-
Evoke Pharma (EVOK) Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti
-
Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™
